Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025
ATM Offering Program
Commissions	$ 1,040	$ 2,353
Offering costs	137	148
Commissions and offering costs			$ 2,403
Issuance of common stock/equity offering, net of commissions and offering costs	$ 45,059	$ 102,091	$ 98,248
ATM Offering Program \| Common Stock
Issuance of common stock/equity offering, net of commissions and offering costs (in shares)	5,624,053	12,280,637	32,854,486
Issuance of common stock/equity offering, net of commissions and offering costs	$ 1	$ 1	$ 3
ATM Offering Program \| Additional Paid-in Capital
Issuance of common stock/equity offering, net of commissions and offering costs	45,058	102,090	98,245
ATM Offering Program \| Total ImmunityBio Stockholders’ Deficit
Issuance of common stock/equity offering, net of commissions and offering costs	$ 45,059	$ 102,091	98,248
Registered Direct Offering
Offering costs			127
Issuance of common stock/equity offering, net of commissions and offering costs			$ 13,051
Registered Direct Offering \| Common Stock
Issuance of common stock/equity offering, net of commissions and offering costs (in shares)			29,024,768
Issuance of common stock/equity offering, net of commissions and offering costs			$ 3
Registered Direct Offering \| Additional Paid-in Capital
Issuance of common stock/equity offering, net of commissions and offering costs			13,048
Registered Direct Offering \| Total ImmunityBio Stockholders’ Deficit
Issuance of common stock/equity offering, net of commissions and offering costs			$ 13,051